Further evidence gathering and analysis, decision on whether to proceed with the case
September 2017 to November 2018
Consideration of parties’ written and oral representations on the statement of objections; further evidence gathering and analysis; issue of draft penalty statements and letter of facts; receipt and consideration of parties’ representations on letters of facts and draft penalty statements
Statement of objections issued to new addressees
March to May 2017
Receipt of written and oral representations on the statement of objections
Statement of objections issued
September to December 2016
Further information gathering and analysis of information requests
Decision to continue with the investigation
August 2016 to September 2016
Investigation and analysis including further information requests and stakeholder meetings
March to July 2016
Initial investigation: information gathering, including issuance of formal or informal information requests and parties’ responses. CMA analysis and review of parties’ responses to information requests. Potential state of play meetings with parties under investigation
Supplementary statement of objections
12 February 2020: The CMA issued a supplementary statement of objections in relation to its hydrocortisone investigations. The CMA has been conducting three separate investigations into alleged excessive and unfair pricing, anti-competitive agreements and abusive conduct in relation to the supply of hydrocortisone tablets in the UK. Due to the interrelationship of the facts and allegations in the three hydrocortisone investigations, the CMA brought them together and revised certain aspects of its provisional findings in the respective statements of objections through this supplementary update, including taking account of further evidence which has been obtained since the original statements of objections were issued. Please see the Hydrocortisone case page for more information.
Statement of objections issued to new parties
9 August 2017: The CMA issued a statement of objections to Intas Pharmaceuticals Limited and Accord Healthcare Limited, which acquired Actavis UK in January 2017, alleging that Actavis UK has breached and continues to breach UK and EU competition law by charging excessive and unfair prices in relation to the supply of hydrocortisone tablets in the UK and proposing to find them jointly and severally liable for the alleged infringements from their period of ownership.
Statement of objections
16 December 2016: The CMA issued a statement of objections alleging that Actavis UK has breached UK and EU competition law by charging excessive and unfair prices in relation to the supply of hydrocortisone in the UK.
The investigation is under Chapter II of the Competition Act 1998 (CA98).
No conclusion should be drawn that there has been an infringement of competition law at this stage and the recipients of the statement of objections will now have an opportunity to respond to the allegations.
The CMA will consider any representations it receives before any decision is taken as to whether competition law has in fact been infringed.